20:18:20 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



WPD Pharmaceuticals Inc
Symbol WBIO
Shares Issued 111,520,388
Close 2020-07-09 C$ 0.39
Market Cap C$ 43,492,951
Recent Sedar Documents

ORIGINAL: WPD now hopes to file fiscal 2019 financials by July 20

2020-07-10 12:18 ET - News Release

Received by email:

File: '\\doc\emailin\20200710 091203 Attachment WPD - News Release Status filing of Annual Financial Statements for De
--->ce....docx'




CW15282516.1









WPD Pharmaceuticals Provides Update on 
Audited Financial Statements
Vancouver, British Columbia / July 10, 2020 - WPD Pharmaceuticals Inc. (the "Company") (CSE: WBIO) (FSE: 8SV1), the Co
--->mpany provides this update on the status of the audit of its consolidated annual financial statements for the year end
--->ed December 31, 2019 (the "2019 Financial Statements"), the management discussion and analysis and the related officer
---> certifications.  As previously announced, the British Columbia Securities Commission issued a management cease trade 
--->order on June 16, 2020 because the Company was unable to timely file the 2019 Financial Statements, and the Company is
---> filing this status update in accordance with National Policy 12-203, Management Cease Trade Orders, which requires bi
--->-weekly updates by way of news releases.
The Company's auditors are working on the audit, and the Company now expects to file it on or about July 20, 2020. 

About WPD Pharmaceuticals 
WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and dev
--->elopment of medicinal products involving biological compounds and small molecules.  WPD has licensed in certain countr
--->ies 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at i
--->nstitutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academ
--->ic centers in Poland.
WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Mol
--->eculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearin
--->g sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, 
--->manufacturing and sales rights, among other things.  The sublicense territory from CNS Pharmaceuticals and Moleculin B
--->iotech includes for most compounds 31 countries in Europe and Asia, including Russia.
On Behalf of the Board
'Mariusz Olejniczak'
 Mariusz Olejniczak
CEO, WPD Pharmaceuticals  
Contact
Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com 


Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts respons
--->ibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate act
--->ivities, events or developments that the Company can develop effective drugs against cancer and possibly viruses.  Fac
--->tors which may prevent the forward looking statement from being realized include that competitors or others may succes
--->sfully challenge a granted patent and the patent could be rendered void; we may be unable to raise sufficient funding 
--->for our research; we may be unable to expend sufficient funds on research to keep our sublicense rights; our grant app
--->lications may not be successful or if successful, we may not meet the requirements to receive the grants awarded; that
---> our drugs don't provide positive treatment, or if they do, the side effects are damaging; competitors may develop bet
--->ter or cheaper drugs; and we may be unable to obtain regulatory approval for any drugs we develop; the filing of the 2
--->019 Financial Statements as well as the financial statements and related documents for the first fiscal quarter of 202
--->0 and the projected timing. Readers should refer to the risk disclosure included from time-to-time in the documents th
--->e Company files on SEDAR, available at www.sedar.com.  Although the Company believes that the assumptions inherent in 
--->these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they 
--->should not be relied upon and there can be no assurance that any of them will prove to be accurate.  Finally, these fo
--->rward-looking statements are made as of the date of this press release and the Company assumes no obligation to update
---> them except as required by applicable law.
 







© 2024 Canjex Publishing Ltd. All rights reserved.